Welcome to the
European Biotechnology Network!

The European Biotechnology Network is dedicated to facilitating co-operation between professionals in biotechnology and the life sciences all over Europe.

The non-profit organisation brings research groups, universities, SMEs, large companies and indeed all actors in biotechnology together to build and deliver partnerships.

Read more about our activities here.


The Network has been making an assessment of the potential impact of Brexit on the scientific community in Europe. We just launched a survey and we would appreciate if you participate here.

Latest Catch

  • © kentoh / Fotolia

    iOmx hits the ground running

    22.09.2016 Backed by MPM Capital and Sofinnova, immuno-oncology specialist iOmx Therapeutics has raised €40m in its first round of financing. The German company had just been founded in spring.

    iOmx Therapeutics develops first-in-class cancer therapeutics addressing novel immune checkpoint modulators on tumour cells. Now, the Martinsried-based company has managed to raise €40m to continue building its pipeline of drug candidates against half a dozen of its proprietary immune-oncology targets. MPM Capital and Sofinnova Partners are contributing the lion’s share of the investment. Wellington Partners and Merck Ventures are chipping in a „smaller portion“, iOmx chairman Sebastian Meier-Ewert told European Biotechnology’s German-language sister magazine transkript

    “IOmx is one of the first companies to find targets based on the signature of actual immunosuppressive molecules on the surface of the primary tumour,” Meyer-Ewert told

Featured Events

Our Corporate Members are


All events

Membership - Join the Network!

Individual Membership for natural persons is free, while Corporate Membership, for companies, institutions and research groups start from €500 p.a.
Click here to apply for network membership!


European Biotechnology Network AISBL

Rue de la Science 14b
1040 Brussels, Belgium

Tel: +32 27 33 72 37

Funding Hub Strategic Partnership

European Biopharmaceutical Enterprises